• 대한한방내과학회지
• /
• 제21권3호
• /
• pp.511-514
• /
• 2000

We diagnosis two patients who have severe vertigo and gait inbalance as ‘dizziness due to retention of phlegm’ (痰暈) and gave Zexie-tang(澤瀉湯). They improved enable to walk balance and no more vetigo. Therefore we could assume that Ku-ren-xuan-mao(苦人眩冒) which is the main symptom of Zexie-tang means the vertigo and gait imbalance due to vestibular disorder.

• 대한한방내과학회지
• /
• 제32권3호
• /
• pp.371-386
• /
• 2011

Background : Vertigo is a very common complaint in clinical practice. The number of patients who complain of vertigo has been increasing due to rapid growth of the elderly population. This study was designed to review the clinical features and success of oriental medical treatment of positional vertigo. Methods : This observation was made on 70 subjects diagnosed with positional vertigo. They were hospitalized in the Semyung University Oriental Medicine Hospital. Results : The results were as follows 1. Female patients (82.9%) were more than male patients. The most common age group was 8th decade and the patients rapidly increased after the 5th decade of age. 2. The most common past history of positional vertigo was hypertension, the second was cerebral infarction, and the third was hyperlipidemia. 3. In the oriental medicine diagnosis, phlegm-dampness syndrome (痰濕交阻 眩暈) was the most common disease (92.9%), and in western medicine, BPPV was the most (82.9%). 4. In herbal medication, Banhabaekchulchunma-tang gami (45.7%) was the most commonly used, the second being Taeksa-tang (30%). 5. The vertigo score of 94.3% patients improved and none got worse. 6. In general characteristics, men over 64 years improved best. Past history had no effect on the improvement of vertigo. 7. The sooner patients visited hospital after onset, the shorter hospitalization time was. Conclusions : Vertigo attacks patients well in advanced age, with various causative diseases. Oriental medical treatments have considerable effects on positional vertigo, especially treated with Banhabaekchulchunma-tang gami and Taeksa-tang.

• 대한한방내과학회지
• /
• 제44권3호
• /
• pp.485-505
• /
• 2023

Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: The search was conducted using keywords such as "dyslipidemia", "hyperlipidemia", "taeksa tang", "zexie tang", and "takusha to" in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane's risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web. Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008). Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.